Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors

International Journal of Gynecological Pathology

Volumn 27, Issue 3, 2008, Pages 326-332

  Chen, Longwen ^a   Yang, Bin ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bizarre leiomyoma; Cellular leiomyoma; Ki 67; Leiomyosarcoma; p16 expression; p53 expression

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS MYOMA; UTERUS TUMOR; LEIOMYOMA; UTERUS CANCER;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LEIOMYOMA; LEIOMYOSARCOMA; NEOPLASM PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 50349087113     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31815ea7f5     Document Type: Article

References (24)

1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-438
2. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcomas 1989-1999. Gynecol Oncol 2004;93:204-208
3. Evans HL, Chawla SP, Simpson C, et al. Smooth muscle neoplasms of the uterus other than ordinary leiomyomas: a study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988;62:2239-2247 (Pubitemid 18261867)
4. Christopherson WM, Williamson EO, Gray LA. Leiomyosarcoma of the uterus. Cancer 1972;29:1512-1517
5. Hart WR, Billman JK. A reassessment of uterine neoplasms originally diagnosed as leiomyosarcomas. Cancer 1978;41:1902-1910
6. Tavassoli FA, Devilee P. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
7. Zhai YL, Nikaido T, Fujii S. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 1999;75:453-459
8. Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the radiation therapy oncology group protocol 86-10. J Clin Oncol 2003;34:3328-3334 (Pubitemid 46606267)
9. Feakins RM, Nickols CD, Bidd H, et al. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 2003;34:1276-1282 (Pubitemid 38018141)
10. Kawaguchi K, Oda Y, Saito T, et al. Mechanisms of inactivation of the p16 in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003;201:487-495 (Pubitemid 37408271)
11. Makitie AA, MacMillian C, Ho J, et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003;9:2177-2184 (Pubitemid 36687641)
12. Kalof AN, Cooper K. p16 immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 2006;13:190-194
13. Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 2005;96:62-66 (Pubitemid 39612418)
14. O'Nell CJ, McBride HA, Connolly LE, et al. Uterine leiomyosarcomas are characterized by high p16, p53, and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumors of uncertain malignant potential. Histopathology 2007;50:851-858
15. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: a clinicalpathologic study of 213 cases. Am J Surg Pathol 1994;18:535-558
16. Hart WR. Problematic uterine smooth muscle neoplasms [letter]. Am J Surg Pathol 1997;21:252.
17. Downes KA, Hart WR. Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up. Am J Surg Pathol 1997;21:1261-1270
18. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol 1995;14:134-142
19. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986;10:611-617 (Pubitemid 16011866)
20. Mayerhofer K, Lozanov P, Bodner L, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand 1995;83:1085-1088
21. Leisler AL, Anderson SE, Nonaka D, et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol 2006;101:86-91. (Pubitemid 43303564)
22. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32:984-987
23. Jeffers MD, Farquharson MA, Richmond JA, et al. P53 immunoreactivity and mutation of the p53 gene in smooth muscle tumors of the uterine corpus. J Pathol 1995;177:65-70.
24. Anderson SE, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer 2006;16:849-853